The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

With a capital investment of US$66.1 million and 63 new jobs created, this expansion includes the addition of 63,000 square feet of administrative space and more than 28,000 square feet of laboratory ...

U.S. Animal Health Country Managing Director at Boehringer Ingelheim. "Each year, we invest nearly 12 percent of our sales into researching and developing products that will advance the health of ...

STORY German pharmaceutical company sees great benefits from CIIE spillover effectSHOOTING TIME Recent footageDATELINE Nov 10 2024LENGTH 00011 ...

Boehringer Ingelheim has been awarded a multi-year contract to continue to provide antigen and vaccine supply capability as ...

Earlier this month, Boehringer Ingelheim, a leader in animal health, said it is stepping up its efforts to combat rabies in ...

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of ...